

ForPatients

by Roche

Neoplasms Respiratory Tract Neoplasms Non-Small Cell Lung Cancer (NSCLC) Lung Neoplasm Neuroendocrine Carcinoma Solid Tumors Medullary Thyroid Cancer Thoracic Neoplasms Thyroid Cancer Head and Neck Neoplasms

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

Trial Status
Completed

Trial Runs In
13 Countries

Trial Identifier
NCT03037385
2016-004390-41,BLU-667-1101
BO42863

The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

Trial Summary:

This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in participants with medullary thyroid cancer (MTC), RET-altered NSCLC and other RET-altered solid tumors.

Hoffmann-La Roche
Sponsor

Phase 1/Phase 2
Phase

NCT03037385 2016-004390-41,BLU-667-1101 BO42863
Trial Identifiers

Eligibility Criteria:

Gender
All

Age
≥18 Years

Healthy Volunteers
No